According to the news, JDRF, the biggest non-profit supporter of research firms that conduct experiments on type 1 diabetes’ drugs, has agreed to provide funding to Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) for its phase II trials on the safety and efficacy of LX4211 drug. In its phase II testing, LX4211 will be used on younger individuals; it will be administered to around 76 individuals, with type 1 diabetes, under the age of 30 years. For a period of 12 weeks, these individuals will be given either a placebo or a daily dose of 400mg of LX4211.

Talking about the stocks of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), in the last trading session, these closed at a price of $1.56. As far as company’s institutional and insider ownership is concerned, the figures are reported to be around 85.90% and 0.40% respectively. Moreover, the company’s total outstanding shares reached the figures of 514.94 million shares.

Coming to the share prices of Bluebird bio Inc (NASDAQ:BLUE), the company, on the last trade day, saw a decrease of 1.18 percent and closed its shares at a price of $33.94. The company has a 52 week high of $35.55 and a 52 week low of $33.55. Moreover, it has a market capitalization of $831.94 billion whereas 24.51 million company’s shares are recorded to be outstanding shares.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) stocks saw an increase when the company announced positive results for its phase III study; the company was running efficacy tests for its pain killer, BEMA buprenorphine.

In last trading session, total trading volume of BioDelivery Sciences International, Inc. (NASDAQ:BDSI)’s stocks reached 2.28 million shares, much greater than its average volume of 1.28 million shares. Moreover, the stocks started at $675.29 and closed at $13.94.

Coming to Acasti Pharma Inc (NASDAQ:ACST), the company’s stocks jumped up following the news of its successful trials. The company focuses on development of drugs used in the prevention and treatment of cardio metabolic disorders. The company has completed its Phase I and Phase II of the trials, and rumors have it that it will be successful in getting FDA approval for the execution of Phase III in the United States.

Talking about Acasti Pharma Inc (NASDAQ:ACST)’s stock prices, in the last trading session, the company’s stocks started at a price of $1.10 and ended at a price of $1.08. The highest figures hit by the stocks were recorded to be $1.22, with a weekly performance of -6.78 percent.

Lastly, Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) disclosed that the company is offering around 2,017,349 shares to the public. According to the company, the shares belong to the common stock rank and the selling price will be $40 per share.

In last trade session, the shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) started at a price of $40.50 and closed at a price of $40.00. The intra-day range for company’s stocks was recorded to be $37.77 to $40.99 whereas the total market capitalization of the company reached the figures of $1.20 billion.

Get Free Updates and Stock Alerts!

*We only send one email per week